ChemotherapyFDA-approvedSecond-line
Docetaxel
How it works
Interferes with cell division, causing cancer cells to die.
Cancer types
Efficacy
In clinical trials, around 25% of patients achieved an objective response, with median overall survival of approximately 6 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Radium-223 with Docetaxel in Prostate Cancer Patients | Prostate Cancer | phase-3 | — | Source → |
| Evaluating a New Treatment Combination for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Study Examines Effectiveness of Docetaxel and Ramucirumab for Lung Cancer Symptoms | Lung Cancer | observational | The pleural effusion control rate was 87%, and the cerebral edema control rate was 26%. | Source → |
| Testing BNT324 for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Combination Therapy for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| ONC-392 vs Docetaxel for Lung Cancer That Has Progressed | Lung Cancer | phase-3 | — | Source → |
| Testing New Treatments for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a Combination of Medications for HER2-Positive Early-Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Study of Darolutamide in Combination with Androgen Deprivation Therapy and Docetaxel for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing a New Treatment to Docetaxel for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Comparing BL-B01D1 to Docetaxel in Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Evaluating a Lower-Dose Chemotherapy Combination for Older Women with Early-Stage Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Green Tea and Quercetin Combined with Chemotherapy in Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Testing ADI-PEG 20 with Gemcitabine and Docetaxel for Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Ivonescimab with Docetaxel for Advanced Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Docetaxel with Hormonal Therapy and Apalutamide for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing Treatments for Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Treatment Combination Shows Promise for Prostate Cancer Patients | Prostate Cancer | phase-2 | At week 12, 67.7% of patients showed a response in prostate-specific antigen (PSA) levels. | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Evaluating Nivolumab and Docetaxel for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| New Treatment Combination Shows Promise for HER2 Positive Breast Cancer | Breast Cancer | phase-3 | Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004). | Source → |
| Study of a New Medicine for Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Insights into Prostate Cancer Treatment Options | Prostate Cancer | meta-analysis | Darolutamide + docetaxel + ADT showed significant benefit over docetaxel + ADT, ADT and standard-nonsteroidal-antiandrogen + ADT in all analyses. | Source → |
| New Insight into Docetaxel Resistance in Prostate Cancer | Prostate Cancer | lab-study | Treatment with an OTUB2 inhibitor resensitized resistant CRPC to docetaxel. | Source → |
| Severe Neutropenia Risk in Prostate Cancer Patients on Cabazitaxel | Prostate Cancer | observational | — | Source → |
| Liposomes Help Deliver Cancer Medicine to Prostate Cancer Cells | Prostate Cancer | review | — | Source → |
| Eugenol Derivatives Enhance Chemotherapy Effectiveness in Prostate Cancer Cells | Prostate Cancer | lab-study | — | Source → |
| Chemotherapy Combination Affects Lung Cancer Cells in Lab Experiments | Lung Cancer | lab-study | — | Source → |
| Hospitalization Risks Vary for Prostate Cancer Patients on Different Treatments | Prostate Cancer | observational | — | Source → |
| Early Docetaxel and Enzalutamide for Prostate Cancer: New Insights | Prostate Cancer | phase-3 | Among those assigned no enzalutamide, OS was longer with the planned use of early docetaxel (HR 0.90, 95% CI 0.82-0.98), especially in high-volume disease. | Source → |
| METTL14's Role in Lung Cancer Progression and Docetaxel Resistance | Lung Cancer | lab-study | — | Source → |
| Atezolizumab Compared to Docetaxel in Lung Cancer Treatment | Lung Cancer | meta-analysis | Atezolizumab had better efficacy than docetaxel for overall survival (HR: 0.77, 95% CI: 0.73 to 0.81). | Source → |
| New Nanoparticle Delivery System Shows Promise for Breast Cancer Treatment | Breast Cancer | lab-study | The cRGD-HA-CDU@DTX system exhibited a 64.12% tumor growth reduction. | Source → |
| New Delivery System for Cancer Drug Shows Promise | Prostate Cancer | lab-study | Docetaxel-bound nanoparticles significantly reduced the viability of the tumor cell compared to the healthy cell in a dose-dependent manner, especially at 24 (50.14 ± 13.25 to 22.32 ± 5.51 at 100 µg/mL) h and 48 (41.46 ± 2.22 to 18.80 ± 2.81 at 100 µg/mL) h. | Source → |
| New Nanofibrous Mats Deliver Cancer-Fighting Medicine Directly to Prostate Cancer Sites | Prostate Cancer | lab-study | — | Source → |
| Prostate Cancer Cells May Resist Chemotherapy Due to Protein Interactions | Prostate Cancer | lab-study | — | Source → |
| AGD1 Complex May Reduce Effectiveness of Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Traditional Chinese Medicine May Help Overcome Prostate Cancer Resistance to Treatment | Prostate Cancer | lab-study | — | Source → |
| DRG2 levels predict response to PARP inhibitors in prostate cancer cells | Prostate Cancer | lab-study | — | Source → |
| Real-world safety of docetaxel for lung cancer treatment | Lung Cancer | observational | — | Source → |
| Cancer Cells Develop Resistance to Chemotherapy | Breast Cancer | lab-study | — | Source → |
| GRIM-19's Role in Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| New way to deliver cancer drug may reduce side effects | Breast Cancer | lab-study | The encapsulated drug indicated higher cytotoxicity on MCF-7 cells and the half inhibitory concentration (IC) value was 2 µg/ml after 72 h. | Source → |
| Prostate Cancer Cells May Resist Treatment Due to Exosome-Released Molecule | Prostate Cancer | lab-study | — | Source → |
| Liquid Biopsy Predicts Treatment Response in Prostate Cancer Patients | Prostate Cancer | phase-3 | LBRB-positive patients had no benefit from continuing enzalutamide with docetaxel (HR = 0.78, 95% CI = 0.41-1.48, p = 0.44; RMST: 7.9 vs 7.1 mo, p = 0.50). | Source → |
| Researchers Identify Pathway Behind Docetaxel Resistance in Prostate Cancer Cells | Prostate Cancer | lab-study | — | Source → |
| Targeted Nanoparticles Show Promise in Treating Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Combining drugs to overcome cancer resistance | Lung Cancer | lab-study | — | Source → |
| Dexamethasone May Help Reduce Hand-Foot Syndrome in Breast Cancer Patients | Breast Cancer | observational | Development of all-grade hand-foot syndrome in all treatment cycles was significantly lower in the 8 mg group (50.0%) than in the 4 mg group (73.0%). | Source → |
| Cost-Effectiveness of Sotorasib for Lung Cancer Patients in China | Lung Cancer | phase-3 | — | Source → |
| Previous Cancer Treatment May Affect Neutropenia Risk in Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Targeting Glutamine Metabolism in Resistant Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Prostate Cancer Protein Degradation May Help Combat Resistance to Docetaxel | Prostate Cancer | lab-study | — | Source → |
| Docetaxel treatment creates large, polyploid cancer cells in ovarian cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Turmeric Compound with Standard Prostate Cancer Treatment May Improve Effectiveness | Prostate Cancer | lab-study | — | Source → |
| NOTCH3 linked to docetaxel resistance in prostate cancer | Prostate Cancer | lab-study | — | Source → |
| Combining two drugs slows prostate cancer growth in lab experiments | Prostate Cancer | lab-study | The combination of CUDC-101 and DTX significantly reduced tumor growth, as evidenced by lower tumor weight and volumes. | Source → |
| Symptoms of Breast Cancer Patients Before and After Chemotherapy | Breast Cancer | observational | — | Source → |
| New Lung Cancer Treatment Combination Shows Mixed Results | Lung Cancer | phase-3 | The clinical benefit rate was 75.5% for sitra + nivo and 64.5% for docetaxel. | Source → |
| Generic vs. Brand Docetaxel in Breast Cancer Treatment | Breast Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.